Clinical Trials
21 trialsNCT05768139 2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT07174336 2026-05-22
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT06757634 2026-05-18
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity Inc
Phase 3 Recruiting
NCT07347600 2026-05-18
reaINAVO
Hoffmann-La Roche
Recruiting
NCT06377852 2026-05-13
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
American Society of Clinical Oncology
Phase 3 Recruiting
NCT05683418 2026-04-22
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Totus Medicines
Phase 1 Recruiting
NCT05238922 2026-04-14
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1 Recruiting
NCT04841148 2026-04-09
PALAVY
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT04360941 2026-04-06
PAveMenT
Royal Marsden NHS Foundation Trust
Phase 1 Recruiting
NCT04654208 2026-03-31
SIRI
Pfizer
Recruiting
NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT07002177 2026-01-07
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Forward Pharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT05563220 2026-01-06
ELEVATE
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT04563507 2025-12-15
Combined Immunotherapies in Metastatic ER+ Breast Cancer
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT05867251 2025-11-19
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06062498 2025-10-20
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Northwestern University
Phase 2 Recruiting
NCT04567420 2025-10-16
DARE
Criterium, Inc.
Phase 2 Recruiting
NCT05216432 2025-09-22
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Relay Therapeutics, Inc.
Phase 1 Recruiting
NCT06805812 2025-02-03
PALMARES-2
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Recruiting
NCT06307249 2024-03-12
PTST_PALBEVA
Lebanese University
Phase 1 Recruiting
NCT05766410 2023-03-16
ORACLE-RIPA
National Taiwan University Hospital
Phase 2 Recruiting